Literature DB >> 14982728

Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.

Trygve Holmøy1, Frode Vartdal.   

Abstract

The association between multiple sclerosis and Epstein-Barr virus infection could involve Epstein-Barr virus-specific T cells, provided that these T cells get access to the intrathecal compartment. We report that CD4+ T cells from the cerebrospinal fluid of six out of six multiple sclerosis patients, and four out of six patients with other neurological diseases, recognized autologous B cells transformed with Epstein-Barr virus. The cerebrospinal fluid T-cell responses were predominantly HLA-DR restricted. These T cells did not recognize B cells activated through stimulation of CD40 or the inducible autoantigen alphaB crystalline. These findings support that the immunological response to Epstein-Barr virus could contribute to the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982728     DOI: 10.1080/13550280490261671

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  26 in total

Review 1.  Multiple sclerosis in time and space--geographic clues to cause.

Authors:  J F Kurtzke
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

2.  Epstein-Barr virus and multiple sclerosis.

Authors:  A Ascherio; M Munch
Journal:  Epidemiology       Date:  2000-03       Impact factor: 4.822

3.  T-lymphocyte entry into the central nervous system.

Authors:  W F Hickey; B L Hsu; H Kimura
Journal:  J Neurosci Res       Date:  1991-02       Impact factor: 4.164

4.  Novel HLA-DR2 and -DR3 haplotypes among Norwegian Caucasians.

Authors:  K S Ronningen; A Spurkland; T Iwe; L M Sollid; F Vartdal; E Thorsby
Journal:  Tissue Antigens       Date:  1991-04

5.  Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs.

Authors:  T Ishigami; C A White; M P Pender
Journal:  Eur J Immunol       Date:  1998-05       Impact factor: 5.532

Review 6.  Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis.

Authors:  J M van Noort; J J Bajramovic; A C Plomp; M J van Stipdonk
Journal:  J Neuroimmunol       Date:  2000-06-01       Impact factor: 3.478

7.  Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis.

Authors:  S Cepok; M Jacobsen; S Schock; B Omer; S Jaekel; I Böddeker; W H Oertel; N Sommer; B Hemmer
Journal:  Brain       Date:  2001-11       Impact factor: 13.501

8.  Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.

Authors:  Barbara Savoldo; Michael L Cubbage; April G Durett; John Goss; M Helen Huls; Zhensheng Liu; Lopez Teresita; Adrian P Gee; Paul D Ling; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

9.  A functional and structural basis for TCR cross-reactivity in multiple sclerosis.

Authors:  Heather L E Lang; Helle Jacobsen; Shinji Ikemizu; Christina Andersson; Karl Harlos; Lars Madsen; Peter Hjorth; Leif Sondergaard; Arne Svejgaard; Kai Wucherpfennig; David I Stuart; John I Bell; E Yvonne Jones; Lars Fugger
Journal:  Nat Immunol       Date:  2002-09-03       Impact factor: 25.606

10.  EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis.

Authors:  A C van Sechel; J J Bajramovic; M J van Stipdonk; C Persoon-Deen; S B Geutskens; J M van Noort
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

View more
  9 in total

Review 1.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence.

Authors:  A Ascherio; K L Munger
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

2.  Epstein-Barr virus and disease activity in multiple sclerosis.

Authors:  D Buljevac; G J J van Doornum; H Z Flach; J Groen; A D M E Osterhaus; W Hop; P A van Doorn; F G A van der Meché; R Q Hintzen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

3.  Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.

Authors:  K L Munger; L I Levin; E J O'Reilly; K I Falk; A Ascherio
Journal:  Mult Scler       Date:  2011-06-17       Impact factor: 6.312

4.  Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein.

Authors:  Trygve Holmøy; Espen Østhagen Kvale; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

Review 5.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

6.  Potential impact of B cells on T cell function in multiple sclerosis.

Authors:  Sara Ireland; Nancy Monson
Journal:  Mult Scler Int       Date:  2011-03-24

Review 7.  Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy.

Authors:  Michael P Pender; Scott R Burrows
Journal:  Clin Transl Immunology       Date:  2014-10-31

Review 8.  Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.

Authors:  Andreas Lossius; Jorunn N Johansen; Øivind Torkildsen; Frode Vartdal; Trygve Holmøy
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

9.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.

Authors:  Barbara Serafini; Barbara Rosicarelli; Diego Franciotta; Roberta Magliozzi; Richard Reynolds; Paola Cinque; Laura Andreoni; Pankaj Trivedi; Marco Salvetti; Alberto Faggioni; Francesca Aloisi
Journal:  J Exp Med       Date:  2007-11-05       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.